Healix Announces First Real-World Study of Immune Globulin Subcutaneous 16.5% (Cutaquig®) Featured in the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
SUGAR LAND, TX – (May 7, 2020) Healix Infusion Therapy is pleased to announce that its collaborative research study regarding Immune Globulin Subcutaneous 16.5% (Cutaquig®) is now accessible in the AAAAI Annual Meeting Virtual Poster Hall. The study by authors Richard...
Happy National Nurses Week (May 6-12) from Healix!
The team at Healix would like to recognize and thank nurses across the nation for their dedication to the nursing profession and the time they sacrifice away from their loved ones to care for those in need. Nurses play a critical role not only in our healthcare system...
A 2-Year Analysis of 30-Day Hospital Readmissions and Cost Benefits of Septicemia Outpatient Treatment in a Physician Office Infusion Center (POIC)
Presented on October 7, 2015 Barry Statner, MD, CM FRCPC, FIDSA Fernando S. Alvarado, MD, MPH, TM Brian Metzger, MD, MPH Richard M. Mandel, MD, FIDSA Jorge R. Bernett, MD H. Barry Baker, MD, FACP Alfred E. Bacon III, MD Claudia P. Schroeder, PharmD, PhD Lucinda J. Van...
Recent Comments